CAS: 59751-72-3

Gentamicin C2a is an aminoglycoside antibiotic, which is a complex of compounds derived from the fermentation of the bacterium *Micromonospora purpurea*. Its mode of action involves binding to the bacterial 30S ribosomal subunit, thereby inhibiting protein synthesis and resulting in the bactericidal effect on susceptible strains. The disruption of protein synthesis prevents the growth and replication of bacteria, effectively killing them. Gentamicin C2a is primarily used in the treatment of severe infections caused by Gram-negative bacteria, such as *Pseudomonas aeruginosa*, *Escherichia coli*, and *Klebsiella pneumoniae*. It is also sometimes effective against certain Gram-positive bacteria. The versatility of Gentamicin C2a allows it to be used in various clinical settings, including combating life-threatening systemic infections, complicated urinary tract infections, and severe respiratory infections. Usage must be carefully monitored due to potential nephrotoxic and ototoxic side effects, especially with prolonged use. The antibiotic is frequently administered via intravenous or intramuscular injection, ensuring rapid delivery to the site of infection to achieve optimal therapeutic outcomes.